Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Thymus Neoplasms × NET × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 29 Gastro-enteropancreatic neuroendocrine tumor 5 Carcinoid Tumor 4 Adenoma, Islet Cell 3 Serotonin Syndrome 2 Parkinson Disease 2 Neuroblastoma 2 Neoplasms 2 Congenital Hyperinsulinism 2 Thymus Neoplasms 1 Non functioning pancreatic endocrine tumor 1 Neuroendocrine Tumors in Lung 1 Neuroectodermal Tumors, Primitive 1 Neoplasm Metastasis 1 Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms 1 Lymphoma, Follicular 1 Liposarcoma 1 Lewy Body Disease 1 Insulinoma 1 Hypoglycemia 1 Hyperinsulinism 1 Flushing 1 Fibrosarcoma 1 Disease 1 Diarrhea 1 Carcinoid Tumors, Intestinal 1 Brain Neoplasms 1 Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

Everolimus 1 177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05918302 2026-03-06

LEVEL

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting

Thymus Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡